Last reviewed · How we verify
NCT00920257
A Phase I, Open-Label, First-Time-In-Human Study of the Oral AKT Inhibitor GSK2141795
Completed
Phase 1
Last updated 13 November 2017
What this trial tests
Phase 1 trial testing GSK2141795 in Cancer in 77 participants. Completed in 17 April 2013.
Timeline
16 June 2009
Primary endpoint
17 April 2013
17 April 2013
17 April 2013
Quick facts
| Lead sponsor | GlaxoSmithKline |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 77 |
| Start date | 16 June 2009 |
| Primary completion | 17 April 2013 |
| Estimated completion | 17 April 2013 |
| Sites | 7 locations across Canada, United States |
Drugs / interventions tested
- GSK2141795 — full drug profile →
Conditions studied
- Cancer — all drugs for Cancer →
Sponsor
GlaxoSmithKline — full company profile →
Who can join
18 and older, any sex, with Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is a first time in human, Phase I, open-label, dose-escalation study of the oral AKT inhibitor GSK2141795 in subjects with solid tumors or lymphomas.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention.
Davis NM, Sokolosky M, Stadelman K, Abrams SL, et al · · 2014 · cited 186× · PMID 25051360 · DOI 10.18632/oncotarget.2209 -
Maximising the potential of AKT inhibitors as anti-cancer treatments.
Brown JS, Banerji U. · · 2017 · cited 184× · PMID 27919797 · DOI 10.1016/j.pharmthera.2016.12.001 -
The Warburg effect: evolving interpretations of an established concept.
Chen X, Qian Y, Wu S. · · 2015 · cited 177× · PMID 25277420 · DOI 10.1016/j.freeradbiomed.2014.08.027 -
Small is beautiful: insulin-like growth factors and their role in growth, development, and cancer.
Maki RG. · · 2010 · cited 157× · PMID 20975071 · DOI 10.1200/jco.2009.27.5040 -
Role of PI3K-AKT-mTOR Pathway as a Pro-Survival Signaling and Resistance-Mediating Mechanism to Therapy of Prostate Cancer.
Pungsrinont T, Kallenbach J, Baniahmad A. · · 2021 · cited 148× · PMID 34681745 · DOI 10.3390/ijms222011088 -
Multidrug-resistant breast cancer: current perspectives.
Martin HL, Smith L, Tomlinson DC. · · 2014 · cited 84× · PMID 24648765 · DOI 10.2147/bctt.s37638 -
Combating pancreatic cancer with PI3K pathway inhibitors in the era of personalised medicine.
Conway JR, Herrmann D, Evans TJ, Morton JP, et al · · 2019 · cited 75× · PMID 30396902 · DOI 10.1136/gutjnl-2018-316822 -
The Akt signaling pathway: an emerging therapeutic target in malignant melanoma.
Madhunapantula SV, Mosca PJ, Robertson GP. · · 2011 · cited 68× · PMID 22157148 · DOI 10.4161/cbt.12.12.18442
Verify or expand the search:
- PubMed search for NCT00920257
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of GSK2141795
Trials testing the same drug.
- NCT01941927 — Trametinib With GSK2141795 in BRAF Wild-type Melanoma · Phase 2 · completed
- NCT01266954 — An Open Label Study To Investigate the Pharmacokinetics and Pharmacodynamics of Repeat Escalating Doses of the Oral AKT · Phase 1 · completed
- NCT01138085 — Safety, Pharmacokinetics (PK) of AKT and MEK Combination · Phase 1 · completed
Other recruiting trials for Cancer
Currently open trials in the same condition.
- NCT07390045 — Exercise and Cognitive Rehabilitation Interventions for Older Cancer Survivors · NA · recruiting
- NCT07528547 — Hypersight and Ethos In Pediatric Radiotherapy · NA · recruiting
- NCT07481890 — Feasibility and Efficacy of the EMDR Toolbox Method in Cancer Patients. · NA · recruiting
- NCT07402057 — Implementation and Evaluation of a Program Aimed at Facilitating Palliative Care Conversations · NA · recruiting
- NCT07305740 — On-Trac: An Online Intervention for Cancer Survivors Managing Anxiety · NA · recruiting
Other GlaxoSmithKline trials
Trials by the same sponsor.
- NCT07569081 — A Study Evaluating the Efficacy and Safety of Momelotinib in Participants With Vacuoles, E1-enzyme, X-linked, Autoinflam · Phase 2, PHASE3 · not yet recruiting
- NCT07406347 — A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Infants Receiving 3-dose · Phase 1 · not yet recruiting
- NCT07286266 — A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Platinum-resistant Ovarian Cancer (BEH · Phase 3 · not yet recruiting
- NCT07286331 — A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Recurrent Endometrial Cancer (BEHOLD-E · Phase 3 · not yet recruiting
- NCT07406334 — A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Toddlers 12 to 15 Months · Phase 1 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
Data sources for this page
- Trial protocol + status: ClinicalTrials.gov NCT00920257 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by GlaxoSmithKline
- Last refreshed: 13 November 2017
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00920257.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing